X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CIPLA AJANTA PHARMA/
CIPLA
 
P/E (TTM) x 19.9 43.9 45.4% View Chart
P/BV x 8.6 3.6 237.9% View Chart
Dividend Yield % 0.7 0.4 196.5%  

Financials

 AJANTA PHARMA   CIPLA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
CIPLA
Mar-17
AJANTA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,720622 276.6%   
Low Rs1,103458 240.7%   
Sales per share (Unadj.) Rs194.6181.9 107.0%  
Earnings per share (Unadj.) Rs45.212.9 351.3%  
Cash flow per share (Unadj.) Rs50.329.3 171.6%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.4 153.1%  
Book value per share (Unadj.) Rs132.0155.7 84.8%  
Shares outstanding (eoy) m88.77804.51 11.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.33.0 244.2%   
Avg P/E ratio x31.242.0 74.4%  
P/CF ratio (eoy) x28.118.4 152.3%  
Price / Book Value ratio x10.73.5 308.2%  
Dividend payout %17.715.5 113.8%   
Avg Mkt Cap Rs m125,299434,516 28.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m2,57026,338 9.8%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m17,275146,302 11.8%  
Other income Rs m1662,287 7.3%   
Total revenues Rs m17,442148,589 11.7%   
Gross profit Rs m5,80724,758 23.5%  
Depreciation Rs m45113,229 3.4%   
Interest Rs m491,594 3.1%   
Profit before tax Rs m5,47412,222 44.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,798 81.2%   
Profit after tax Rs m4,01410,354 38.8%  
Gross profit margin %33.616.9 198.6%  
Effective tax rate %26.714.7 181.3%   
Net profit margin %23.27.1 328.3%  
BALANCE SHEET DATA
Current assets Rs m7,63987,370 8.7%   
Current liabilities Rs m2,71533,081 8.2%   
Net working cap to sales %28.537.1 76.8%  
Current ratio x2.82.6 106.5%  
Inventory Days Days4387 49.7%  
Debtors Days Days7962 126.3%  
Net fixed assets Rs m6,914111,567 6.2%   
Share capital Rs m1771,609 11.0%   
"Free" reserves Rs m11,442123,645 9.3%   
Net worth Rs m11,721125,254 9.4%   
Long term debt Rs m14936,454 0.4%   
Total assets Rs m14,814209,532 7.1%  
Interest coverage x112.98.7 1,302.9%   
Debt to equity ratio x00.3 4.4%  
Sales to assets ratio x1.20.7 167.0%   
Return on assets %27.45.7 481.0%  
Return on equity %34.28.3 414.3%  
Return on capital %46.58.5 547.4%  
Exports to sales %55.134.2 161.2%   
Imports to sales %6.08.3 72.0%   
Exports (fob) Rs m9,52750,050 19.0%   
Imports (cif) Rs m1,03812,203 8.5%   
Fx inflow Rs m10,42251,066 20.4%   
Fx outflow Rs m1,67817,678 9.5%   
Net fx Rs m8,74433,388 26.2%   
CASH FLOW
From Operations Rs m3,26423,824 13.7%  
From Investments Rs m-2,093-13,127 15.9%  
From Financial Activity Rs m-1,186-13,239 9.0%  
Net Cashflow Rs m-15-2,478 0.6%  

Share Holding

Indian Promoters % 73.8 16.0 461.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 1.6 12.2 12.7%  
FIIs % 7.6 23.7 32.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.0 26.2 64.9%  
Shareholders   20,968 161,166 13.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Energy Stocks Witness Buying(11:30 am)

After opening the day in green, Share markets in India witnessed volatile trading activity and are presently trading marginally above the dotted line.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 22, 2017 01:16 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS